The premise for the trial is to determine whether AI technologies can be used to predict if a patient will be susceptible to allergic responses given a specific environmental scenario. The predictive models are based on various factors, such as physical characteristics, hereditary characteristics, location and exposure to weather, and physical activity.
Blockchain technology will allow those participating in the trial to provide personal health insights, which will be logged into a blockchain for data security and eventually analyzed by AI technology.
“Blockchain is very useful when there are so many actors in the system,” IBM Watson Health Chief Science Officer Shahram Ebadollahi said in a statement. “It enables the ecosystem of data in healthcare to have more fluidity, and AI allows us to extract insights from the data.”
For more trends in cryptocurrencies, visit ETFTrends.com